Tirzepatide Half-Life Calculator
Tirzepatide has an elimination half-life of approximately 118 hours (about 5 days) — shorter than semaglutide but still long enough to support once-weekly subcutaneous dosing. As a dual GIP/GLP-1 receptor agonist, tirzepatide has a distinct molecular structure from semaglutide; its half-life is driven by albumin binding via a C20 fatty diacid modification. The visualizer models concentration buildup across injection cycles and projects how long tirzepatide remains pharmacologically active after the last dose.
Interactive tool
Half-Life Visualizer
The visualizer runs entirely in your browser. Select Tirzepatide in the compound dropdown to model your schedule.
What You Enter
- Starting dose (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg)
- Number of weeks to model (1–24)
- Day of week for injection
What You Get
- Week-by-week plasma concentration curve
- Estimated time to steady-state (approximately 4 weeks of weekly dosing)
- Projected clearance date after final dose
- Annotation showing steady-state band
From calculator to tracker
The half-life visualizer pairs with the PeptideScholar tirzepatide dose tracker, which lets you log actual injection dates alongside the pharmacokinetic model. The tracker also provides optional refill reminders timed to your supply.
Frequently Asked Questions
Frequently Asked Questions
This tool and content are for informational purposes only. Pharmacokinetic estimates are based on published FDA-label population data and do not account for individual variation in renal function, body composition, or co-medications. Do not use this tool to make clinical decisions without consulting your prescribing physician.
Sources
- 1. Mounjaro (tirzepatide) Prescribing Information — Clinical PharmacologyFDA / Eli Lilly • 2023Claim type: clinicalView source →
- 2. Zepbound (tirzepatide) Prescribing Information — Clinical PharmacologyFDA / Eli Lilly • 2023Claim type: clinicalView source →
- 3. Clinical Pharmacology of TirzepatideClinical Pharmacokinetics • 2022Claim type: clinicalView source →
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.